Table 5.
Association of PFS, OS and DCR with various variables
| PFS | ||||
|---|---|---|---|---|
| Prognostic Variables | HR (95% CI) | p value | Adjusted HR (95% CI) | p value |
| Previous Chemotherapy | ||||
| Yes | 1.0 | 1.0 | ||
| No | 0.59 (0.36–0.97) | 0.037 | 0.60 (0.36–0.98) | 0.04 |
| Baseline FDG uptake | ||||
| SUVmax <5 | 1.0 | 1.0 | ||
| SUVmax ≥5 | 2.18 (1.35–3.53) | <0.05 | 1.91 (1.16–3.12) | 0.01 |
| Baseline 68Ga DOTATATE uptake | ||||
| SUVmax ≥20 | 1.0 | 1.0 | ||
| SUVmax <20 | 2.19 (1.35–3.56) | <0.05 | 1.63 (1.0–2.68) | 0.05 |
| Site of primary | ||||
| Small intestinal NET | Not performed due to insufficient number | |||
| Large intestine | 1.0 (0.03–1.54) | 0.12 | ||
| Pancreas | 1.24 (0.58–2.65) | 0.57 | ||
| Lung | 1.44 (0.50–4.16) | 0.49 | ||
| Mediastinal | 4.66 (1.47–14.7) | <0.05 | ||
| Total cumulative dose of InLuDOTA PRRT | ||||
| ≥29.6 GBq | 1.0 | 1.0 | ||
| <29.6 GBq | 3.89 (2.14–7.08) | <0.05 | 1.21 (0.44–3.32) | 0.7 |
| No. of InLuDOTA PRRT cycles | ||||
| ≥5 cycles | 1.0 | 1.0 | ||
| <5 cycles | 5.62 (3.14–10.07) | <0.05 | 4.11 (1.55–10.91) | <0.05 |
| OS | ||||
| Prognostic Variables | HR (95% CI) | p value | Adjusted HR | p value |
| Baseline 68Ga-DOTATATE uptake | ||||
| SUVmax ≥20 | 1.0 | 1.0 | ||
| SUVmax <20 | 2.46 (1.36–4.44) | <0.05 | 1.31 (0.71–2.44) | 0.38 |
| Presence of bony metastases | ||||
| No | 1.0 | 1.0 | ||
| Yes | 2.13 (1.14–3.95) | 0.017 | 2.13 (1.13–4.01) | 0.019 |
| Site of primary | ||||
| Small intestinal NET | 1.0 | Not performed due to insufficient number | ||
| Large intestine | - | |||
| Pancreas | 1.03 (0.38–2.77) | 0.95 | ||
| Lung | 2.27 (0.72–7.15) | 0.16 | ||
| Mediastinal | 8.70 (2.75–27.5) | <0.05 | ||
| Total cumulative dose of InLuDOTA PRRT | ||||
| ≥29.6 GBq | 1.0 | 1.0 | ||
| <29.6 GBq | 6.84 (2.87–16.26) | <0.05 | 0.83 (0.18–3.68) | 0.80 |
| No. of InLuDOTA PRRT cycles | ||||
| ≥5 cycles | 1.0 | 1.0 | ||
| <5 cycles | 11.77 (4.91–28.22) | <0.05 | 12.90 (2.85–58.40) | <0.05 |
| p value for DCR | ||||
| Yes | No | p values | ||
| Baseline FDG uptake | ||||
| SUVmax <5 | 279 (93.3%) | 20 (6.7%) | ||
| SUVmax ≥5 | 143 (84.6%) | 26 (15.4%) | 0.02 | |
| 68Ga-DOTATATE uptake | ||||
| SUVmax ≥20 | 311 (92.8%) | 24 (7.2%) | ||
| SUVmax <20 | 111 (83.5%) | 22 (16.5%) | 0.002 | |
| Site of primary | ||||
| Small intestinal NET | 107 (93%) | 8 (7%) | ||
| Large intestine | 43 (100%) | 0 (0%) | ||
| Pancreas | 131 (91%) | 13 (9%) | ||
| Lung | 31 (88.6%) | 4 (11.4%) | ||
| Mediastinal | 7 (63.6%) | 4 (36.4%) | 0.05 | |
| Bony metastases | ||||
| Yes | 71 (83.5%) | 14 (16.5%) | ||
| No | 351 (91.6%) | 32 (8.4%) | 0.023 | |
| Baseline serum CgA level | ||||
| <400 ng ml−1 | 177 (95.7%) | 8 (4.3%) | ||
| ≥400 ng ml−1 | `227 (87%) | 34 (13%) | <0.05 | |
| Total cumulative dose of InLuDOTA PRRT | ||||
| ≥29.6 GBq | 175 (95.1%) | 9 (4.9%) | ||
| <29.6 GBq | 247 (87%) | 37 (13%) | <0.05 | |
| No of InLuDOTA PRRT cycles | ||||
| ≥5 cycles | 217 (96%) | 9 (4%) | ||
| <5 cycles | 205 (84.7%) | 37 (15.3%) | <0.05 | |